Sarah C. Rutherford

Nivolumab+AVD in Advanced-Stage Classic Hodgkin’s Lymphoma

Alex F. Herrera, Michael LeBlanc, Sharon M. Castellino et al. · New England Journal of Medicine · 2024 · 200 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

SWOG S1826, a randomized study of nivolumab(N)-AVD versus brentuximab vedotin(BV)-AVD in advanced stage (AS) classic Hodgkin lymphoma (HL).

Alex F. Herrera, Michael LeBlanc, Sharon M. Castellino et al. · Journal of Clinical Oncology · 2023 · 117 citations

Medicine, Oncology, Pharmacotherapy +17

Phase I study of the anti-CD74 monoclonal antibody milatuzumab (hLL1) in patients with previously treated B-cell lymphomas

Peter Martin, Richard R. Furman, Sarah C. Rutherford et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2015 · 49 citations · Full text

Pharmacy, Oncology, Pharmacology +17

Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study

David Qualls, Nicholas Lambert, Paolo F. Caimi et al. · Blood · 2023 · 46 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

Multicenter Phase 2 Study of Oral azacitidine (CC-486) plus CHOP as initial treatment for peripheral T-cell lymphoma

Jia Ruan, Alison J. Moskowitz, Neha Mehta–Shah et al. · Blood · 2023 · 45 citations · Full text

Medicine, Oncology, Pharmacotherapy +8